Articles On Suda Pharmaceuticals (ASX:SUD)
Title | Source | Codes | Date |
---|---|---|---|
Dr Boreham’s Crucible: Arovella Therapeutics
This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin By Tim Boreham ASX code: ((ALA)) Shares on issue: 1,050,775,660 Market cap: $157.6m... |
FNArena | SUD | 3 months ago |
Check Up: These biotech themes got billions in VC funding. These ASX stocks could benefit
A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m... |
Stockhead | SUD | 2 years ago |
New Portfolio Addition: Arovella Therapeutics
Disclosure: The authors of this article and owners of Next Investors, S3 Consortium Pty Ltd, and associated entities, own 13,631,579 ALA shares. S3 Consortium Pty Ltd has been engaged by ALA to share our commentary on the progress of our in... |
FinFeed | SUD | 2 years ago |
Dr Boreham’s Crucible: Is Paul Hopper’s star power enough to get Radiopharm Theranostics beaming?
He’s baaack! Fresh from founding and listing immune-oncology play Chimeric, Paul Hopper can add Radiopharm Theranostics (ASX:RAD) to his boardroom rota after the nuclear medicine play listed on the ASX on Thursday – albeit limply. The count... |
Stockhead | SUD | 3 years ago |
SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile
SUDA Pharmaceuticals (SUD) has its lead product for short-term insomnia, ZolpiMist, approved by the Chile Ministry of Health SUDA’s partner, Teva Pharmaceuticals, submitted the application to the Chilean authority in May 2021 and was grant... |
themarketherald.com.au | SUD | 3 years ago |
Weed Week: California legalises hemp and Aussie medicinal cannabis use hits all-time high
Last week California Governor Gavin Newsom signed Assembly Bill (AB-45), formally permitting the sales of hemp-derived CBD products in the state. Hemp has been legalised at the US federal level since 2018, but state agencies have been slow... |
Stockhead | SUD | 3 years ago |
Weed Week: Amazon scraps marijuana drug tests and Victorian council considers cannabis crops
Retail giant Amazon has rejigged its cannabis policy, allowing employees who were previously fired for testing positive for marijuana to reapply for jobs. The company has now excluded marijuana from its comprehensive pre-employment drug scr... |
Stockhead | SUD | 3 years ago |
Weed Week: Cannabis-infused drinks market could reach US$2.8 billion by 2025
The Boston Beer Company (NYSE:SAM) is set to launch a new range of non-alcoholic cannabis-infused drinks in Canada with the help of Australian listed Althea Group Holdings’ (ASX:AGH) subsidiary. Peak processing Solutions will research and d... |
Stockhead | SUD | 3 years ago |
Suda Pharmaceuticals (ASX:SUD) appoints Dr John Maher
03 Sep 2021 - Suda Pharmaceuticals (ASX: SUD) has appointed Dr John Maher to its scientific advisory board for the iNKT cell therapy platform. |
FNN | SUD | 3 years ago |
Check Up: Dimerix and ImpediMed announced breakthroughs, while earnings dominate news flow in August
Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat... |
Stockhead | SUD | 3 years ago |
Weed Week: Cannabis trade shows and Europe imports medicinal marijuana
Virginia is the latest US state to legalise marijuana and they’re celebrating with the first annual CannaFest VA cannabis trade show on September 19. The event will feature a concert, and a custom car and motorcycle exhibition but no, you c... |
Stockhead | SUD | 3 years ago |
Closing Bell: Energy shares push ASX higher
It was another positive close for the Australian bourse today with energy the standout sector. The ASX 200 closed 0.17% higher at 7,503 points while the ASX Emerging Companies Index gained 1.1% to close at 2,262 points. Leading the charge w... |
Stockhead | SUD | 3 years ago |
Check up: Rhinomed (ASX:RNO) soars with NSW COVID contract, and genetic testing fails to impress
It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N... |
Stockhead | SUD | 3 years ago |
Weed Week: Cannabis ice cream deal and Israeli CBD market worth US$475m by 2025
Massachusetts based cannabis operator MariMed has just announced a joint collaboration with the legendary Boston ice cream brand Emack & Bolio’s® to create a line-up of cannabis-infused vegan and dairy ice cream. The ice cream will cont... |
Stockhead | SUD | 3 years ago |
ASX health stocks: EMV’s brain scanner is completed and ready for testing, stock price jumps 16pc
The ASX200 health stocks index (XHJ) fell by 0.14% this morning, compared to the broader index which rose by 0.35%. Medical imaging specialist, EMVision (ASX:EMV), has rocketed by 16% after announcing that 1st Gen portable brain scanner has... |
Stockhead | SUD | 3 years ago |
Check Up: Hexima roars 70pc on clinical trials, while Bionomics heads for a US dual listing
The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du... |
Stockhead | SUD | 3 years ago |
Suda Pharmaceuticals appoints senior cell and gene therapy manufacturing expert
The new appointee’s responsibilities include technology transfer, manufacturing, and quality aspects for the production of the cell therapy for clinical development stages. |
Proactive Investors | SUD | 3 years ago |
ASX Health Stocks: Hydrix implants world’s first Guardian heart attack alert system
The biggest winner in health stocks today was Hydrix (ASX:HYD) – up 9.68% off the back of news that Angel Medical Systems had completed its first commercial implantation in the US of the Guardian device – a cardiac detection monitor and pat... |
Stockhead | SUD | 3 years ago |
Weed Week: Cannabis business degrees, cornering Germany’s €200M market and Hanks Kerchiefs hits stores
The Community College of Denver (CCD) has just launched a cannabis business program in Colorado. The new program offers students the opportunity to earn an Associate of Applied Science degree designed to prepare them to become business mana... |
Stockhead | SUD | 3 years ago |
Suda Pharmaceuticals ends June quarter with $6.7 million in bank as it prepares to move forward its iNKT cell therapy platform licence
The biotechnology company released its fourth-quarter report, unveiling cash receipts for the quarter of $68,000 and net outflow of $909,000 from operating activities for the quarter. |
Proactive Investors | SUD | 3 years ago |
Check Up: Rhythm (ASX:RHY) plans US expansion, the US$1.5b dog dermatitis market and data dumps drive stocks down
It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by Rhinomed (ASX:RNO)... |
Stockhead | SUD | 3 years ago |
Closing Bell: ASX recovers early losses to close 0.17pc higher
After starting the day in negative territory, the Australian bourse recovered to finish higher. The ASX 200 closed 0.17 per cent up, at 7,348 points while the ASX Emerging Companies Index closed 0.71 per cent up at 2,203. Most sectors were... |
Stockhead | SUD | 3 years ago |
Weed Week: The CanCoin, cannabis tourism, and record medicinal product sales in Australia
This week Technicorum Holdings announced an upcoming token sale and launch of The CanCoin – a cannabis token designed to solve market friction and monetisation in the European cannabis market and to help build blockchain-based solutions for... |
Stockhead | SUD | 3 years ago |
Suda Pharmaceuticals' introduce novel iNKT cell therapy platform from Imperial College London
|
Proactive Investors | SUD | 3 years ago |
Check up: A mixed bag for ASX health stocks as FDA decides fates at the flip of a coin
It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals... |
Stockhead | SUD | 3 years ago |
Cannabis stocks celebrate Pershing ownership change
Cannabis stocks have welcomed the change in ownership of Pershing Australia from Bank of New York Mellon (BNYM) to Finclear Pty Ltd which – effective immediately – will allow the trading of cannabis securities on the ASX. In late 2019, BNYM... |
Stockhead | SUD | 3 years ago |
Hot Money Monday: Prospa comes in from the cold with six-day rally
Each week, Stockhead recaps ASX stocks that are “running hot” as deduced by the Relative Strength Index (RSI). The RSI is a technical gauge which measures how trading momentum is affecting the price action. A reading of 70 is seen as the le... |
Stockhead | SUD | 3 years ago |
Weed Week: Connecticut and Mexico on board cannabis bandwagon, as Rinehart enters the industry
Connecticut has become the latest US state to legalise recreational use of marijuana. The state’s governor has just signed a bill to allow people aged 21 and older to possess and consume marijuana, making it the 19th US state to do so. Here... |
Stockhead | SUD | 3 years ago |
Hot Money Monday: Afterpay fires up after a big monthly gain
Each week, Stockhead recaps ASX stocks that are “running hot” as deduced by the Relative Strength Index (RSI). The RSI is a technical gauge which measures how trading momentum is affecting the price action. A reading of 70 is seen as the le... |
Stockhead | SUD | 3 years ago |
ScoPo’s Powerplays: Buying opportunities in a volatile week and stock downgrades
Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Theme of the week Healthcare... |
Stockhead | SUD | 3 years ago |
Suda Pharma pops 44pc on cap raise; Acrux and other biotechs whet investor appetites
Plenty of action on the biotech front today has provided ASX investors with some mouth-watering gains. Suda Pharma (ASX:SUD) led the pack, popping by as much as 44 per cent after announcing an oversubscribed $3.65 million capital raise. The... |
Stockhead | SUD | 3 years ago |
Closing Bell: Today’s biggest small cap movers on the ASX
Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading day. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intrad... |
Stockhead | SUD | 3 years ago |
SUDA licenses iNKT cell therapy platform from Imperial College London
SUDA Pharmaceuticals (ASX:SUD) has announced it has signed a global, exclusive agreement with Imperial College London for a novel invariant Natural Killer T cell therapy platform. |
BiotechDispatch | SUD | 3 years ago |
Last Orders: ASX sheds nearly 2 per cent to start the week
It was an ugly day on Australia’s bourse following the plunge on Wall Street on Friday. The ASX 200 lost 1.81 per cent, closing at 7,235 points while the ASX Emerging Companies Index shed 2.56 per cent, closing at 2,093. The selling was spa... |
Stockhead | SUD | 3 years ago |
Weed Week: Amazon all-in on marijuana; free joints for jabs and Creso Pharma dual-listed in US
The US cannabis sector received a big lift after Amazon announced that job applicants at its offices and warehouses will no longer be drug-tested for marijuana use. Delivery drivers, however, will still be tested. The company also said it w... |
Stockhead | SUD | 3 years ago |
Check Up: As Alzheimer’s grabs the spotlight, these ASX biotech stocks also impressed
Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U... |
Stockhead | SUD | 3 years ago |
Weed Week: Major shifts in US legislation set to open the door for some ASX cannabis stocks
There was plenty of action in the US regulatory front within the cannabis sector this week. A couple of major legislations during the week could potentially shake up the US cannabis industry. The Marijuana Opportunity Reinvestment and Expun... |
Stockhead | SUD | 3 years ago |
Invion led a group of ASX cancer stocks up after promising news
It was a good day for some of ASX-listed cancer therapy stocks yesterday, with three companies releasing seperate announcements that sent their share prices higher. Cancer therapy stocks Invion (ASX:IVX), Immutep (ASX:IMM), and Imugene (ASX... |
Stockhead | SUD | 3 years ago |
Weed Week: Europe or North America, where’s the place to be for ASX cannabis stocks?
In 2021, which of Europe and North America is the place to be for ASX cannabis stocks? The case for Europe A few years ago there would’ve been no question that it was North America with Canada legalising recreational cannabis as well as h... |
Stockhead | SUD | 3 years ago |
Weed Week: Finally, a cannabis drug is on Australia’s Pharmaceutical Benefits Scheme
A cannabis-based drug has been listed on Australia’s Pharmaceutical Benefits Scheme for the first time, as medical marijuana gains increased acceptance. The move means that an estimated 116 Aussies with a rare form of epilepsy known as Drav... |
Stockhead | SUD | 3 years ago |
Weed Week: 4/20 can’t help ASX cannabis companies
April 20 has come and gone, but ASX cannabis companies aren’t getting that high — they’re actually low. Of the 36 pot companies in the space, 27 have lost ground over the last fortnight. Just seven have advanced. Gains were led by Wide Open... |
Stockhead | SUD | 3 years ago |
Weed Week: Australian medical cannabis prescriptions are soaring
The number of medical cannabis prescriptions issued under Australia’s special access scheme just keeps on growing. There were a record 9,959 SAS Category B marijuana prescriptions issued in March, two and a half times the number from a year... |
Stockhead | SUD | 3 years ago |
Weed Week: Oz cannabis revenue expected to double in 2021 as patients soar
Australia’s medical marijuana industry is showing strong growth, according to an industry-leading biannual report. The Freshleaf Analytics report, released this morning, says that patient numbers have grown 15-fold over the past two and a h... |
Stockhead | SUD | 3 years ago |
Check Up: Oneview leads healthcare sector after ‘investor awareness’ pact
Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return... |
Stockhead | SUD | 3 years ago |
Weed Week: US pot legalisation picks up steam, and the Big Apple could be next
Pot legalisation is creeping across the US state by state, and a major market could be about to join their ranks. Reports out of New York indicate that lawmakers in the Empire State are close to signing a new bill legalising recreational ca... |
Stockhead | SUD | 3 years ago |
How is SUDA Pharmaceuticals (ASX:SUD) Placed for 2021?
Summary SUDA Pharmaceuticals Limited (ASX:SUD) is anticipated to make significant progress in its product pipeline in 2021. The healthcare company plans to secure new technologies that fit within its current areas of focus. SUDA also... |
Kalkine Media | SUD | 3 years ago |
SUDA Pharmaceuticals (ASX:SUD) Boosts Cash Balance via A$2.7Mn Capital Raising
Summary SUDA Pharmaceuticals Limited (ASX:SUD) has raised A$2.7 million via successful completion of Placement Offer. The capital raising has provided SUDA with a strong cash balance to proceed with its drug development activities over... |
Kalkine Media | SUD | 4 years ago |
SUDA Pharmaceuticals Limited (ASX:SUD) To Raise A$2.76Mn In Oversubscribed Placement
Summary SUDA Pharmaceuticals (ASX:SUD) has obtained firm commitments for a A$2.76 million capital raising. Funds raised from the placement will support the Company in product developments for twelve months and aid in evaluating new ass... |
Kalkine Media | SUD | 4 years ago |
SUDA Pharmaceuticals announces 'firm commitments' on capital raise
SUDA Pharmaceuticals (ASX:SUD), a company focussed on oromucosal drug delivery, has announced it has received "firm commitments" for a placement to raised over $2.7 million. |
BiotechDispatch | SUD | 4 years ago |
SUDA Pharmaceuticals (ASX:SUD) Delivers Impressive Performance in 2020
Summary SUDA Pharmaceuticals Limited (ASX:SUD) has recently released its Annual General Meeting presentation on the ASX. The presentation provides an insight into SUDA’s key achievements in 2020 and its focus for the upcoming year. Im... |
Kalkine Media | SUD | 4 years ago |